Literature DB >> 11781702

Familial Mediterranean Fever: association of elevated IgD plasma levels with specific MEFV mutations.

M Medlej-Hashim1, I Petit, S Adib, E Chouery, N Salem, V Delague, M Rawashdeh, I Mansour, G Lefranc, R Naman, J Loiselet, J C Lecron, J L Serre, A Mégarbané.   

Abstract

Familial Mediterranean Fever (FMF) is a recessively inherited disorder, characterized by episodic fever, abdominal and arthritic pain, as well as other forms of inflammation. Some FMF patients present higher IgD serum levels, and it is not yet known whether such an elevation is related to specific genotypes or correlated with a specific phenotype. In order to evaluate the association between known FMF-related mutations and IgD levels in confirmed patients, as well as the correlation between those levels and the presence of specific clinical signs, genotypic analysis and IgD plasma measurements were performed for 148 Lebanese and Jordanian FMF patients. Most common mutational patterns were M694V heterozygotes (19%) and homozygotes (17%), and V726A heterozygotes (18%) and homozygotes (5%), with an additional 11% combining both mutations. Twenty-one patients had higher IgD levels (superior to 100 microg/ml). The risk for higher IgD levels was significantly associated with M694V homozygote status (OR = 6.25) but not with heterozygotic one (OR = 1). Similarly, the risk for higher IgD was also found with V726A homozygotes (OR = 2.2) but not with heterozygotes (OR = 1.05). The use of colchicine was not statistically associated with IgD levels. Clinically, hyper IgD was also found significantly associated with arthritis (OR = 18). Thus, homozygotic status for M694V, and to a lesser extent V726A, is associated with increased risk for higher IgD plasma levels, regardless of colchicine use. Elevated IgD plasma levels are also correlated with the severity of FMF manifestations, and especially with arthritis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781702     DOI: 10.1038/sj.ejhg.5200725

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  7 in total

1.  Recurrent fevers and failure to thrive in an infant.

Authors:  David R Scott; Sarah Chan; Johanna Chang; Lori Broderick; Hal M Hoffman
Journal:  Allergy Asthma Proc       Date:  2013 Sep-Oct       Impact factor: 2.587

Review 2.  Hyperimmunoglobulin D syndrome in childhood.

Authors:  Jeroen C H van der Hilst; Joost Frenkel
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

3.  Hyperimmunoglobulinemia D syndrome in an Arab child.

Authors:  Mohammed Hammoudeh
Journal:  Clin Rheumatol       Date:  2004-07-08       Impact factor: 2.980

4.  MEFV mutations in familial Mediterranean fever: association of M694V homozygosity with arthritis.

Authors:  Abdullah Olgun; Serif Akman; Ismail Kurt; Ahmet Tuzun; Turker Kutluay
Journal:  Rheumatol Int       Date:  2004-01-15       Impact factor: 2.631

5.  A patient with hyper-IgD syndrome in Antalya, Turkey.

Authors:  Erkan Coban; Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2004-02-24       Impact factor: 2.980

6.  Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency.

Authors:  Cécile-Audrey Durel; Achille Aouba; Boris Bienvenu; Samuel Deshayes; Brigitte Coppéré; Bruno Gombert; Cécile Acquaviva-Bourdain; Eric Hachulla; Frédéric Lecomte; Isabelle Touitou; Jacques Ninet; Jean-Baptiste Philit; Laurent Messer; Marc Brouillard; Marie-Hélène Girard-Madoux; Michel Moutschen; Nadia Raison-Peyron; Pascal Hutin; Pierre Duffau; Pierre Trolliet; Pierre-Yves Hatron; Philippe Heudier; Ramiro Cevallos; Thierry Lequerré; Valentine Brousse; Vincent Lesire; Sylvain Audia; Delphine Maucort-Boulch; Laurence Cuisset; Arnaud Hot
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Extensive thrombosis in a patient with familial Mediterranean fever, despite hyperimmunoglobulin D state in serum. [corrected].

Authors:  Kowoon Joo; Won Park; Moon-Hyun Chung; Mie-Jin Lim; Kyong Hee Jung; Yoonseok Heo; Seong-Ryul Kwon
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.